Literature DB >> 18420315

Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine.

Arto Palmu1, Jukka Jokinen, Terhi Kilpi.   

Abstract

Considerably higher vaccine efficacy estimate for clinical acute otitis media (AOM) has been obtained for the 11-valent pneumococcal conjugate vaccine with protein D of Haemophilus influenzae as a carrier (PncPD11) in the POET study than for the 7-valent pneumococcal conjugate vaccine (PncCRM7) in the Finnish Otitis Media (FinOM) Vaccine Trial. We recalculated PncCRM7 efficacy from the FinOM data using a case definition for AOM very close to the POET definition and a definition giving an incidence for AOM in the control group comparable to that obtained in the POET study. The different case definitions had only a slight impact on the vaccine efficacy estimates compared to the original case definitions. We were not able to show that the differences between the study results would be due to the case definitions used.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18420315     DOI: 10.1016/j.vaccine.2008.03.013

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Impact of pneumococcal conjugate vaccination on otitis media: a systematic review.

Authors:  Sylvia Taylor; Paola Marchisio; Anne Vergison; Julie Harriague; William P Hausdorff; Mark Haggard
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

2.  Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials.

Authors:  Mark A Fletcher; Bernard Fritzell
Journal:  Int J Otolaryngol       Date:  2012-06-03

3.  Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial.

Authors:  Menno R van den Bergh; Judith Spijkerman; Kristien M Swinnen; Nancy A François; Thierry G Pascal; Dorota Borys; Lode Schuerman; Ed P F Ijzerman; Jacob P Bruin; Arie van der Ende; Reinier H Veenhoven; Elisabeth A M Sanders
Journal:  Clin Infect Dis       Date:  2012-11-01       Impact factor: 9.079

4.  Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model.

Authors:  Mustafa Bakır; Ozden Türel; Oleksandr Topachevskyi
Journal:  BMC Health Serv Res       Date:  2012-11-09       Impact factor: 2.655

5.  Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.

Authors:  Miguel W Tregnaghi; Xavier Sáez-Llorens; Pio López; Hector Abate; Enrique Smith; Adriana Pósleman; Arlene Calvo; Digna Wong; Carlos Cortes-Barbosa; Ana Ceballos; Marcelo Tregnaghi; Alexandra Sierra; Mirna Rodriguez; Marisol Troitiño; Carlos Carabajal; Andrea Falaschi; Ana Leandro; Maria Mercedes Castrejón; Alejandro Lepetic; Patricia Lommel; William P Hausdorff; Dorota Borys; Javier Ruiz Guiñazú; Eduardo Ortega-Barría; Juan P Yarzábal; Lode Schuerman
Journal:  PLoS Med       Date:  2014-06-03       Impact factor: 11.069

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.